ERBB2 and breast carcinoma: Despite success in treating HER-2 positive breast cancer patients with these therapies, considerable debate continues to exist regarding which method of testing of HER-2 represents the best assessment of a patient’s HER-2 status (Bartlett et al. [2001]; Wolff et al. [2007]; Sauter et al. [2009]; Press et al. [2005]; Hammock et al. [2003]; Troxell et al. [2006]; Tse et al. [2011]; Pauletti et al. [1996]; Pauletti et al. [2000]; Perez et al. [2012]).